title: Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.
abstract: BACKGROUND
  Hospitalization is a costly and distressing event associated with relapse during schizophrenia treatment. No information is available on the predictors of psychiatric hospitalization during maintenance treatment with olanzapine long-acting injection (olanzapine-LAI) or how the risk of hospitalization differs between olanzapine-LAI and oral olanzapine. This study aimed to identify the predictors of psychiatric hospitalization during maintenance treatment with olanzapine-LAI and assessed four parameters: hospitalization prevalence, incidence rate, duration, and the time to first hospitalization. Olanzapine-LAI was also compared with a sub-therapeutic dose of olanzapine-LAI and with oral olanzapine.
  
  
  METHODS
  This was a post hoc exploratory analysis of data from a randomized, double-blind study comparing the safety and efficacy of olanzapine-LAI (pooled active depot groups: 405 mg/4 weeks, 300 mg/2 weeks, and 150 mg/2 weeks) with oral olanzapine and sub-therapeutic olanzapine-LAI (45 mg/4 weeks) during 6 months' maintenance treatment of clinically stable schizophrenia outpatients (n=1064). The four psychiatric hospitalization parameters were analyzed for each treatment group. Within the olanzapine-LAI group, patients with and without hospitalization were compared on baseline characteristics. Logistic regression and Cox's proportional hazards models were used to identify the best predictors of hospitalization. Comparisons between the treatment groups employed descriptive statistics, the Kaplan-Meier estimator and Cox's proportional hazards models.
  
  
  RESULTS
  Psychiatric hospitalization was best predicted by suicide threats in the 12 months before baseline and by prior hospitalization. Compared with sub-therapeutic olanzapine-LAI, olanzapine-LAI was associated with a significantly lower hospitalization rate (5.2% versus 11.1%, p < 0.01), a lower mean number of hospitalizations (0.1 versus 0.2, p = 0.01), a shorter mean duration of hospitalization (1.5 days versus 2.9 days, p < 0.01), and a similar median time to first hospitalization (35 versus 60 days, p = 0.48). Olanzapine-LAI did not differ significantly from oral olanzapine on the studied hospitalization parameters.
  
  
  CONCLUSIONS
  In clinically stable schizophrenia outpatients receiving olanzapine-LAI maintenance treatment, psychiatric hospitalization was best predicted by a history of suicide threats and prior psychiatric hospitalization. Olanzapine-LAI was associated with a significantly lower incidence of psychiatric hospitalization and shorter duration of hospitalization compared with sub-therapeutic olanzapine-LAI. Olanzapine-LAI did not differ significantly from oral olanzapine on hospitalization parameters.
  
  
  BACKGROUND
  ClinicalTrials.gov: NCT00088491.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA. ascher-svanum_haya@lilly.com.
authors.forename: Haya
authors.initials: H
authors.lastname: Ascher-Svanum
authors.forename: Diego
authors.initials: D
authors.lastname: Novick
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Haro
authors.forename: Jordan
authors.initials: J
authors.lastname: Bertsch
authors.forename: David
authors.initials: D
authors.lastname: McDonnell
authors.forename: Holland
authors.initials: H
authors.lastname: Detke
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine
references.citation: Eur Psychiatry. 2011 May;26(4):224-30
references.pmid: 21429717
references.citation: Psychol Med. 1994 Feb;24(1):223-32
references.pmid: 8208887
references.citation: BMJ. 2006 Jul 29;333(7561):224
references.pmid: 16825203
references.citation: Health Econ Rev. 2012 May 04;2(1):9
references.pmid: 22828440
references.citation: World J Biol Psychiatry. 2004 Oct;5(4):201-10
references.pmid: 15543514
references.citation: Am J Psychiatry. 2011 Jun;168(6):603-9
references.pmid: 21362741
references.citation: Eur Neuropsychopharmacol. 2013 Nov;23(11):1383-90
references.pmid: 23477752
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Arch Gen Psychiatry. 1999 Mar;56(3):241-7
references.pmid: 10078501
references.citation: CNS Drugs. 2013 Aug;27(8):637-52
references.pmid: 23780619
references.citation: Schizophr Res. 2011 Apr;127(1-3):83-92
references.pmid: 21257294
references.citation: J Clin Psychiatry. 2008 May;69(5):790-9
references.pmid: 18452346
references.citation: J Clin Psychiatry. 2005 Sep;66(9):1122-9
references.pmid: 16187769
references.citation: J Clin Psychiatry. 2013 Jun;74(6):568-75
references.pmid: 23842008
references.citation: J Psychopharmacol. 2011 May;25(5):567-620
references.pmid: 21292923
references.citation: J Clin Psychiatry. 1996;57 Suppl 9:5-9
references.pmid: 8823344
references.citation: Br J Psychiatry. 2004 Apr;184:346-51
references.pmid: 15056580
references.citation: Schizophr Bull. 2008 Jan;34(1):173-80
references.pmid: 17578893
references.citation: Arch Gen Psychiatry. 1979 Nov;36(12):1283-94
references.pmid: 227340
references.citation: Med Care. 1996 Mar;34(3):220-33
references.pmid: 8628042
references.citation: Schizophr Bull. 1998;24(1):87-98
references.pmid: 9502548
references.citation: J Consult Clin Psychol. 1996 Jun;64(3):602-9
references.pmid: 8698955
references.citation: Psychol Med. 1983 Feb;13(1):177-83
references.pmid: 6133297
references.citation: Schizophr Bull. 1995;21(3):419-29
references.pmid: 7481573
references.citation: BMC Psychiatry. 2011 May 17;11:87
references.pmid: 21586165
references.citation: Lancet. 2012 Jun 2;379(9831):2063-71
references.pmid: 22560607
references.citation: J Clin Psychiatry. 2008 Jan;69(1):47-53
references.pmid: 18312037
references.citation: Clinicoecon Outcomes Res. 2011;3:9-14
references.pmid: 21935327
references.citation: BMC Psychiatry. 2010 Jan 07;10:2
references.pmid: 20059765
references.citation: Psychiatr Clin North Am. 2009 Dec;32(4):863-83
references.pmid: 19944889
references.citation: Am J Psychiatry. 2010 Feb;167(2):181-9
references.pmid: 20008947
references.citation: Int Clin Psychopharmacol. 2012 Sep;27(5):275-82
references.pmid: 22699789
references.citation: Arch Gen Psychiatry. 1997 May;54(5):453-63
references.pmid: 9152099
references.citation: J Psychiatr Res. 2008 Aug;42(10):822-6
references.pmid: 18479709